Preparation, In vitro, Preclinical and Clinical Evaluations of Once Daily Sustained Release Tablets of Aceclofenac

다국어 초록 (Multilingual Abstract)

The objective of the present study was to develop ‘once daily’ sustained release tablets of aceclofenac by direct compression using hydroxypropyl methylcellulose-K4M (HPMC). The solubility studies of aceclofenac were conducted to select suitable dissolution media. The drugexcipient mixtures were subjected to preformulation studies. The tablets were subjected to physicochemical, In vitro drug release and stability studies. Preclinical (anti-inflammatorv, analgesic, pharmacokinetic and toxicity studies) and clinical pharmacokinetic studies were conducted for optimized tablets. Based on the preformulation results, microcrystalline cellulose (MCC), dicalcium phosphate and spray dried lactose (SDL) were selected as directly compressible vehicles. Because of the incompatibility with aceclofenac, SDL was excluded from the study. The physicochemical properties of tablets were found within the limits. By comparing the dissolution profiles with the marketed product, the tablet containing HPMC (45%) and MCC (30%) along with talc and magnesium stearate (1% w/w, each) (tablet B7) was considered as a better formulation. This tablet exhibited almost similar drug release profile in different dissolution media as that of marketed tablet. Tablet B7 was stable in accelerated conditions for 6 months. The composition of this tablet showed almost similar preclinical pharmacological activities compared to marketed tablet composition and did not exhibit any toxicity in rats and mice with respect to tested haematological and biochemical parameters along with bodyweight, food and water intake. The pharmacokinetic study in healthy human volunteers indicated that B7 tablet produced an extended drug release of drug upto 24 h as that of marketed product with almost identical pharmacokinetic parameters.

참고문헌 (Reference)

1 "Stationary office, MHRA, British Pharmacopoeial Commission office, Vol. 1" London 1 : 2005

2 "Rheumatoid Arthritis and Osteoarthritis, Fig. 5. Plasma drug concentration-time curve. Each point is presented as Mean ± SD, n = 6. Marketed=Marketed tablet; Prepared = Prepared tablet (B7)" Churchill Livingstone, London 791-807, 2003

3 "Regulatory considerations in controlled release medication" In Chien 577-578, 1982

4 "Pharmaceutics-The Science of Dosage Form Design. ELBS/ Churchill Livingstone" 1990

5 "Formulation of sustained-release promethazine hydrochloride tablets using hydroxypropyl methylcellulose matrices. Int. J. Pharm." 327-338, 1985

6 "Formulation and In Vitro, In Vivo Evaluation of Extendedrelease Matrix nd ed." Massachusets 2-12, 1999

7 "Effect of hydroxypropyl methylcellulose and hydrogenated castor oil on naproxen release from sustained-release tablets" 2 : 1-8, 2001

8 "Controller of Publications, Vol. 2" Delhi 1996

9 "A review of cellulose ethers in hydrophilic matrices for oral controlled dosage forms. Int. J. Pharm. Tech. Prod. Manuf." 1-9, 1984